异基因造血干细胞移植后病毒感染的防治进展  

Progress of prevention and treatment for viral infection following allogeneic hematopoietic stem cell transplantation

作　　者：杨漾 张义成[1] YANG Yang;ZHANG Yi-cheng(Department of Hematology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Hubei Wuhan 430030,China)

机构地区：[1]华中科技大学同济医学院附属同济医院血液内科,湖北武汉430030

出　　处：《内科急危重症杂志》2023年第2期101-105,共5页Journal of Critical Care In Internal Medicine

基　　金：国家自然科学基金(No:81973998)。

摘　　要：病毒感染是异基因造血干细胞移植(allo-HSCT)常见的并发症,也是导致移植后非复发死亡的重要原因。移植后免疫缺陷是导致病毒感染及再激活的主要因素。随着病毒诊断学的改进,尤其是宏基因组二代测序的普及,大大促进了移植后病毒感染的早期诊断。预防及抢先治疗策略的实施,则进一步控制了移植后潜伏病毒的再激活和病毒感染的严重程度。用于恢复病毒特异性免疫的过继细胞疗法是治疗病毒性疾病的一种很有前途的方法。Viral infection is a common complication of allogeneic hematopoietic stem cell transplantation(allo-HSCT)and an important cause of non-relapse mortality after transplantation.Post-transplant immunodeficiency is the main factor leading to viral infection and re-activation.With the improvement of viral diagnostic techniques,especially the widespread use of metagenomic next-generation sequencing,early diagnosis of viral infection after transplantation has been greatly facilitated.The implementation of prevention and preemptive treatment strategies has further controlled the re-activation of post-transplant latent virus and the severity of viral infection.Adoptive cellular therapy for restoring virus-specific immunity is a promising approach for treating viral diseases.

关 键 词：病毒感染 异基因造血干细胞移植 预防 抢先治疗 病毒特异性T细胞疗法 

分 类 号：R552[医药卫生—血液循环系统疾病]